(Q34662736)

3 August 2017

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain (English)

1 reference

3 August 2017

5

Daniel N Bolon

1 reference

3 August 2017

Timothy R Wagenaar

1

1 reference

3 August 2017

Leyuan Ma

2

1 reference

3 August 2017

Benjamin Roscoe

3

1 reference

3 August 2017

Sung Mi Park

4

1 reference

3 August 2017

Michael R Green

6

1 reference

3 August 2017

15 October 2013

1 reference

Pigment Cell & Melanoma Research

3 August 2017

1 reference

3 August 2017

27

1 reference

3 August 2017

124-133

1 reference

3 August 2017

1

1 reference

describes a project that uses

3 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4260813/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Vemurafenib: the first drug approved for BRAF-mutant cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Fitness analyses of all possible point mutations for regions of genes in yeast

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Experimental illumination of a fitness landscape

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Potent and selective pyrazole-based inhibitors of B-Raf kinase

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

New insight into BRAF mutations in cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Ba/F3 cells and their use in kinase drug discovery

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Mutations of the BRAF gene in human cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260813

Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC.

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FPCMR.12171

The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FPCMR.12171

21 January 2018

Identifiers

DOI

10.1111/PCMR.12171

1 reference

3 August 2017

1 reference

3 August 2017

1 reference